You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Optimizing HaploSeq for whole-genome phased haplotypes in biomedical applications
SBC: ARIMA GENOMICS, INC. Topic: 172DESCRIPTION provided by applicant Phenomenal advances in DNA sequencing technologies have enabled systematic identification of genetic variants in human individuals and the recent FDA marketing authorization of the first next generation genome sequencer signals the arrival of a new era of pharmacogenomics and personalized medicine Nevertheless DNA sequencing alone fails to provide complete i ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Administrative Supplement to restore fee funds
SBC: AMERICAN LIFE SCIENCE PHARMACEUTICALS, INC. Topic: NINDSProject Summary Traumatic brain injuryTBIcauses detrimental behavioral dysfunctions and brain neurodegeneration butunfortunatelythere currently is no effective pharmaceutical TBI treatmentThe underlying PhaseSTTR grant is to develop a new class of TBI drugs that inhibit the protease cathepsin BGenetically deleting the cathepsin B gene in mice results in substantial behavioral and pathology improve ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
A Protective Tetravalent Vaccine Candidate for Dengue Fever Virus
SBC: ALTRAVAX, INC Topic: NIAIDDESCRIPTION provided by applicant There are approximately million cases of dengue fever each year with billion people at risk mostly in low income countries There are four serotypes of dengue fever virus DENV and in its uncomplicated form the disease is worthy of its indigenous name andquot break bone feverandquot An individual may suffer sequential infections with multiple DE ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Protein ProFiler Microfluidic Electrophoresis System for Proteomics
SBC: INNOVAREGI LLC Topic: 400AbstractThe current estimate of the number of human genes is aboutin contrast to the number of presumed proteinswhich likely exceeds one millionThis increased complexity is the result of post transcriptional and post translational modificationsPTMsoccurring at multiple sites and in a quantitative variable mannerThe overwhelming result is a combinatorially expanding complexity of proteoforms that i ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Optimizing Direct Delivery of Nucleic Acid Therapeutics
SBC: FHC, INC. Topic: NIMHProject Summary While nucleic acid therapeutics have shown promise in rodent and nonhuman primate models of CNS diseasesall double blind clinical trials to date have failedOne likely explanation for this failure is poor therapeutic distribution in targeted brain regionsFor examplepost mortem studies of patients with Parkinsonandapos s Disease receiving intraparenchymal injections of AAV NTN demons ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Novel Highly Regenerative and Scalable Progenitor Cell Exosomes for Treating Stroke
SBC: BioTime, Inc. Topic: 100ABSTRACT Stroke is a leading cause of disability worldwideGloballythere aremillion stroke survivors each year who have significant neurological deficits including sensory and motor disabilityleading to excessive socioeconomic burdenCell therapy using primary MSCs has been actively explored by us and others as a therapeutic solution to this unmet medical needHoweversince the therapeutic efficacy of ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
An innovative WGS platform for discovery, annotation, and interpretation of all forms of human genetic variation.
SBC: Base2 Genomics LLC Topic: 172PROJECT SUMMARY Modern DNA sequencing technologies have transformed our ability to interrogate human genomes in a single experimentthereby eliminating the inherent blind spots of gene panels and whole exome sequencingFurthermorerecent speed and economy improvements are driving the cost of whole genome sequencingWGSdown to that of WESthereforewe foresee a transition over the next two years to WGS a ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Development of a Gene and Oligonucleotide Delivery System
SBC: MOLECULAR EXPRESS, INC Topic: NCATSDESCRIPTION provided by applicant The knockdown of targeted genes by anti sense oligonucleotides ODNS and genetic medicines collectively G MEDS holds promise for a variety of therapies The delivery of effective quantities of ODNS to specific cells however has proved to be challenging We propose here a novel approach to ODN delivery that involves enveloped virus like particles EVLPs ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Targeting C/EBP-beta Phosphorylation for the Treatment of Lung Fibrosis
SBC: XFIBRA, LLC Topic: NHLBIDESCRIPTION provided by applicant Activation of lung myofibroblasts LMF is responsible for the development of lung fibrosis in chronic lung diseases of all causes and remarkably LMF clearance by apoptosis may prevent development of lung fibrosis and lung injury and possibly allow recovery from reversal of lung fibrosis There is full agreement among tissue fibrosis experts that inhibiting o ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Innovative Nose-to-Brain Anticancer Drug Transport Facilitated by NEO100
SBC: NEONC TECHNOLOGIES INC Topic: 102Project Summary Abstract Many pharmaceutical agents are highly potentbut are unable to exert substantial therapeutic activity against disorders of the brainbecause the blood brain barrierBBBeffectively prevents their access to the site of intracerebral diseaseFor examplethe majority of glioblastoma patientsdespite the best efforts of current medical caredie within two years after diagnosisHencethe ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health